Most companies in this category publish one flattering number. Enara publishes four, arranged into a ladder that separates lifestyle from older medications from GLP-1s, with time points attached. It is the most quantitatively confident marketing we have reviewed — and not one figure has a source behind it.
The Outcome Ladder
The published figures are 9.8% weight loss at 18 months without medication, 14.9% at 18 months with non-GLP-1 medication and described as consistent through 36 months, and 22% at 18 months with GLP-1 medication. Separately, 91% of members are said to achieve at least 5% loss beyond four years.
Structuring results this way deserves credit. It concedes that the medication is doing most of the work at the top of the ladder, distinguishes drug classes rather than lumping them, and reports at 18 and 36 months rather than stopping at the flattering early window. That is more honest architecture than a single “up to” headline.
The top rung is also broadly credible. Tirzepatide produced roughly 21% mean weight loss at 72 weeks in its registration trial, so 22% at 18 months in a programme that adds a dietitian and structured exercise is at the upper end of plausible rather than beyond it.
What is missing is everything that would let you check any of it: no sample size, no citation, no definition of who was included, and no statement of whether these are completers or everyone who enrolled. On the evidence ladder these sit where company-reported internal data always sits — above testimonials, well below a peer-reviewed trial — regardless of how precise the decimal places look.
The Rung That Looks Too High
The figure worth pausing on is not the GLP-1 one. It is 9.8% at 18 months without medication.
Intensive lifestyle intervention is one of the most heavily studied things in obesity medicine, and the results are consistent and modest: large, well-funded, closely supervised programmes typically produce high single digits at one year, with meaningful regain afterwards. A programme reporting nearly 10% at eighteen months from lifestyle alone is claiming to beat that literature at the point where it usually decays.
This is the rung where survivor selection does the most damage. If the denominator is people still active in the programme at eighteen months, the non-medication group is self-selected for the people it was working for — everyone for whom lifestyle alone was not enough has either added medication or left.
The counter-explanation is real too: a programme with a dietitian, exercise programming, behavioural support and app-based engagement tracking genuinely is more intensive than most lifestyle care, and intensity does predict results. Both stories fit the number. Only the methodology would separate them, and it is not published.
The Four-Year Claim
91% achieving at least 5% loss beyond four years is the most valuable claim on the site if true, because durability is the thing this whole field is worst at. Weight regain after stopping treatment is well documented, and four-year retention data is genuinely scarce.
It is also the claim most exposed to the denominator problem. Four years is a long time for anyone to stay in a weight programme, and the members still present at that point are a heavily filtered group. The bar is also low — 5% is the conventional threshold for clinically meaningful loss, not a description of transformation — which makes a high percentage easier to reach among people who stayed.
If Enara has four-year data on a defined cohort, that is publishable research and would be worth a great deal more than a line on a homepage. As presented, it is an assertion.
What the Programme Actually Is
Underneath the numbers is a legitimately multidisciplinary service: emotional and behavioural assessment, dietitian-designed nutrition, metabolic and hormonal testing, exercise programming and engagement tracking through an app, with a medication review as one component rather than the entire product. It accepts UnitedHealthcare, Blue Cross Blue Shield, Aetna, Cigna and Humana, among others.
That combination — insurance plus a genuine multi-component programme — is rare here, and it is the strongest argument for Enara. It also puts the outcome claims in a more sympathetic light: a service doing this much more than prescribing probably does get better results than a prescription-only competitor. It still has not shown its working.
The disclosure gaps are conventional for the category and disappointing given the rest: medications are never named, no pricing appears, no BMI criteria are stated, and the site refers to serving six states without listing which six.
Provider Facts
| Medications offered | GLP-1 and non-GLP-1 weight management medications; individual drugs are not named |
|---|---|
| Brand-name or compounded | Not stated - the site does not say whether medications are brand-name or compounded |
| Consultation process | Medical care within a multidisciplinary programme including dietitian, exercise and behavioural components |
| Eligibility | Not published - no BMI threshold stated |
| Provider involvement | Medical team plus dietitians and exercise physiologists; individual credentials not published |
| Lab requirements | Metabolic and hormonal testing described as part of the programme; specific panels and cost not published |
| Pharmacy fulfillment | Not published |
| Shipping frequency | Not published - not presented as a mail-order compounding model |
| Support services | Nutrition design, exercise programming, behavioural assessment and app-based engagement tracking |
| Membership fees | Not published |
| Medication fees | Not published |
| Cancellation policy | Not published |
| Refund policy | Not published |
| Insurance | Accepted, including UnitedHealthcare, Blue Cross Blue Shield, Aetna, Cigna and Humana; coverage marked with a qualifying asterisk |
| HSA/FSA | Not published |
| Availability | Stated as six states, which are not listed; company based in San Mateo, California |
Pros and Cons
Pros
- Genuinely multidisciplinary — nutrition, exercise, behaviour, not just a prescription
- Accepts major commercial insurance
- Reports outcomes separately by treatment type rather than as one blended figure
- Reports at 18 and 36 months rather than stopping at an early window
- Concedes that medication drives the top-tier results
- Metabolic and hormonal testing built into the programme
Cons
- No citation, sample size or methodology for any outcome figure
- Lifestyle-only result sits above the published intensive-lifestyle literature
- Four-year retention claim is highly exposed to survivor selection
- Medications are never named
- No pricing published at all
- Says six states without listing them
Who It May Be Best For
A good fit if you want the whole programme rather than the drug — a dietitian, structured exercise and behavioural support alongside medical care — and you have insurance that Enara accepts.
Especially if you have tried prescription-only telehealth and found that having a prescription was not the same as having a plan. This is the opposite end of that trade.
Confirm your state first, since the six are not listed, and get a written cost estimate covering both the programme fee and the medication before enrolling — neither is published anywhere.
Alternatives
knownwell is the closest peer — insurance-billed obesity medicine with in-person clinics and a similar citation gap. Form Health and Calibrate take the programme-led approach too. Our best GLP-1 for weight loss page compares them.
Limitations of This Review
Based on Enara Health’s own published materials at enarahealth.com, checked on 5 September 2026. Every outcome figure discussed is the company’s own claim; we could not verify any of them, and our analysis addresses how they are presented rather than asserting they are wrong. Anything marked not published means we could not find it — pricing and state coverage may be disclosed during an insurance check we did not complete. The comparison figures for tirzepatide and for intensive lifestyle intervention come from the published literature, not from Enara. Nothing here is medical advice.
Frequently Asked Questions
Does Enara Health take insurance?
Yes — it names UnitedHealthcare, Blue Cross Blue Shield, Aetna, Cigna and Humana among accepted plans, with a qualifying asterisk on the coverage claim. No cash prices are published for anyone without those plans.
Are the published results trustworthy?
They are internal, self-reported figures with no sample size, methodology or citation. The GLP-1 figure is consistent with trial data; the lifestyle-only figure sits above what the published lifestyle literature usually shows, which is where we would want the methodology most.
What does it cost?
Not published — neither the programme fee nor medication cost appears anywhere on the site. Ask for both in writing before enrolling.
Which states does it serve?
The site refers to six states without naming them. The company is based in San Mateo, California. Confirm coverage before starting.
Verdict
4.0 / 5 — pricing not published; insurance accepted
A real multidisciplinary obesity programme with insurance behind it, which is worth more than most of what this category sells. It publishes better-structured outcome claims than anyone else here and supports none of them, and it withholds the medications, the prices and the state list.
The point worth carrying beyond this provider: precision is not evidence. A figure quoted to one decimal place with a time point attached reads like a trial result and can still be an unaudited internal count with an unstated denominator. The question to ask of any such number is not how exact it looks but who was left out of it.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Enara Health's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 5, 2026